Vanguard Group Inc. Has $18.52 Million Stock Holdings in Stoke Therapeutics, Inc. $STOK

Key Points

• Vanguard Group Inc. has increased its stake in Stoke Therapeutics by 1.9%, bringing its total holdings to 2,784,202 shares, valued at approximately $18.5 million.
• Several other institutional investors, including JPMorgan Chase and UBS, have also significantly increased their positions in Stoke Therapeutics.
• Stoke Therapeutics reported earnings per share of ($0.40), beating analyst estimates of ($0.57), despite lower revenues of $13.82 million versus a consensus estimate of $31.51 million.

Vanguard Group Inc. increased its stake in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 1.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,784,202 shares of the company's stock after purchasing an additional 53,004 shares during the period. Vanguard Group Inc. owned 5.10% of Stoke Therapeutics worth $18,515,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of STOK. Toronto Dominion Bank bought a new stake in shares of Stoke Therapeutics during the fourth quarter worth $35,001,000. RTW Investments LP lifted its position in Stoke Therapeutics by 10.1% during the 4th quarter. RTW Investments LP now owns 5,123,525 shares of the company's stock valued at $56,512,000 after purchasing an additional 471,240 shares during the period. Tang Capital Management LLC bought a new position in shares of Stoke Therapeutics in the 4th quarter valued at about $3,309,000. Schonfeld Strategic Advisors LLC bought a new position in shares of Stoke Therapeutics in the 4th quarter valued at about $3,218,000. Finally, Dimensional Fund Advisors LP grew its position in shares of Stoke Therapeutics by 103.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 538,900 shares of the company's stock worth $5,943,000 after buying an additional 273,890 shares during the period.

Insiders Place Their Bets

In other news, insider Barry Ticho sold 4,504 shares of Stoke Therapeutics stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $12.82, for a total value of $57,741.28. Following the completion of the transaction, the insider owned 16,775 shares of the company's stock, valued at $215,055.50. This trade represents a 21.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, General Counsel Jonathan Allan sold 13,712 shares of the company's stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $15.00, for a total transaction of $205,680.00. Following the completion of the sale, the general counsel directly owned 19,631 shares in the company, valued at approximately $294,465. The trade was a 41.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 9.50% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on STOK. Jefferies Financial Group initiated coverage on shares of Stoke Therapeutics in a research note on Friday, July 18th. They issued a "buy" rating and a $30.00 price objective on the stock. Needham & Company LLC restated a "buy" rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, July 1st. BTIG Research set a $28.00 price objective on Stoke Therapeutics and gave the company a "buy" rating in a report on Monday, August 18th. Chardan Capital reissued a "buy" rating and issued a $24.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, August 13th. Finally, Wedbush boosted their price objective on shares of Stoke Therapeutics from $16.00 to $22.00 and gave the company an "outperform" rating in a report on Wednesday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating and seven have issued a Buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $25.57.

Stoke Therapeutics Price Performance

Shares of STOK traded up $0.31 during mid-day trading on Wednesday, hitting $19.90. 562,053 shares of the company's stock were exchanged, compared to its average volume of 805,984. Stoke Therapeutics, Inc. has a 52 week low of $5.35 and a 52 week high of $20.45. The company has a market cap of $1.09 billion, a PE ratio of 23.39 and a beta of 1.14. The company has a 50-day simple moving average of $14.42 and a 200 day simple moving average of $10.83.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.57) by $0.17. The company had revenue of $13.82 million for the quarter, compared to analysts' expectations of $31.51 million. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%. On average, analysts anticipate that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.